Cited by 138Nitric Oxide and Endothelin EffectsPulmonary Hypertension Research and TreatmentsCardiovascular Health and Disease Prevention

Nitric oxide in the pulmonary vasculature

Coggins, Matthew P., Bloch, Kenneth D.·2007·Arteriosclerosis Thrombosis and Vascular Biology

Abstract

Homeostasis in the pulmonary vasculature is maintained by the actions of vasoactive compounds, including nitric oxide (NO). NO is critical for normal development of the pulmonary vasculature and continues to mediate normal vasoregulation in adulthood. Loss of NO bioavailability is one component of the endothelial dysfunction and vascular pathology found in pulmonary hypertension (PH). A broad research effort continues to expand our understanding of the control of NO production and NO signaling and has generated novel theories on the importance of pulmonary NO production in the control of the systemic vasculature. This understanding has led to exciting developments in our ability to treat PH, including inhaled NO and phosphodiesterase inhibitors, and to several promising directions for future therapies using nitric oxide-donor compounds, stimulators of soluble guanylate cyclase, progenitor cells expressing NO synthase (NOS), and NOS gene manipulation.

Integrity signals

Registry

Crossref · 10.1161/atvbaha.107.142943

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Coggins, M. P., & Bloch, K. D.
Affiliations
Massachusetts General Hospital (US)
Venue
Arteriosclerosis Thrombosis and Vascular Biology
Published
2007-09
Volume
27
Issue
9
Pages
1877-1885
ISSN
  • 1079-5642 (ISSN-L)
  • 1524-4636
OpenAlex
W2130449101
Cited by
138
References
116
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 5 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 7 · 2016: 5 · 2015: 7 · 2014: 14 · 2013: 8 · 2012: 18
FWCI
1.43
Type
journal article
Language
en
Open access
closed
Locations
  • Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Keywords
nitric oxide, pulmonary vasculature, pulmonary hypertension, endothelial dysfunction, NO bioavailability, vascular regulation, no-signaling, inhaled nitric oxide, phosphodiesterase inhibitors, nitric oxide donors, soluble guanylate cyclase, nitric oxide synthase, progenitor cells
MeSH terms
Animals, Homeostasis, Humans, Hypertension, Pulmonary, Nitric Oxide, Pulmonary Circulation, Signal Transduction, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review